FVIII:C and VWF AUC and half-lives after desmopressin
| . | Median AUC0, tmax, IU/dL/h (no. of patients) . | P* . | Median half-life, h (no. of patients) . | P . |
|---|---|---|---|---|
| VWF:RCo | ||||
| No mutation | 334.1 (19) | — | 12.0 (9) | — |
| 2 N | 372.7 (3) | .53 | 8.8 (2) | .15 |
| D1-D2 | 328.7 (3) | .58 | NM | NA |
| D4-CK | 305.1 (8) | .23 | 6.0 (6) | .39 |
| D′-D3 | 171.9 (16) | .04 | 1.4 (15) | <.001 |
| A1-A3 | 146.1 (14) | .04 | 7.4 (11) | .17 |
| Intronic | 130.0 (5) | .13 | NA | NA |
| Double mutations | 229.3 (9) | .22 | 2.7 (4) | .02 |
| VWF:Ag | ||||
| No mutation | 293.3 (19) | — | 10.8 (8) | — |
| 2 N | 368.7 (3) | .53 | 6.7 (2) | .11 |
| D1-D2 | 371.1 (3) | .53 | NM | NA |
| D4-CK | 345.6 (8) | .90 | 21.6 (6) | .03 |
| D′-D3 | 179.5 (16) | .01 | 2.1 (14) | <.001 |
| A1-A3 | 218.3 (14) | .05 | 9.6 (11) | .84 |
| Intronic | 165.3 (5) | .13 | NA | NA |
| Double mutations | 214.0 (9) | .04 | 4.2 (5) | .72 |
| FVIII:C | ||||
| No mutation | 486.8 (19) | — | 6.2 (9) | — |
| 2 N | 407.1 (3) | .53 | 3.4 (3) | .04 |
| D1-D2 | 442.6 (3) | .53 | NM | NA |
| D4-CK | 686.0 (8) | .07 | 5.4 (6) | .39 |
| D′-D3 | 317.4 (16) | .01 | 2.0 (15) | <.001 |
| A1-A3 | 298.0 (14) | .001 | 6.2 (11) | .65 |
| Intronic | 367.0 (5) | .61 | NA | NA |
| Double mutations | 379.0 (9) | .22 | 3.3 (5) | .09 |
| . | Median AUC0, tmax, IU/dL/h (no. of patients) . | P* . | Median half-life, h (no. of patients) . | P . |
|---|---|---|---|---|
| VWF:RCo | ||||
| No mutation | 334.1 (19) | — | 12.0 (9) | — |
| 2 N | 372.7 (3) | .53 | 8.8 (2) | .15 |
| D1-D2 | 328.7 (3) | .58 | NM | NA |
| D4-CK | 305.1 (8) | .23 | 6.0 (6) | .39 |
| D′-D3 | 171.9 (16) | .04 | 1.4 (15) | <.001 |
| A1-A3 | 146.1 (14) | .04 | 7.4 (11) | .17 |
| Intronic | 130.0 (5) | .13 | NA | NA |
| Double mutations | 229.3 (9) | .22 | 2.7 (4) | .02 |
| VWF:Ag | ||||
| No mutation | 293.3 (19) | — | 10.8 (8) | — |
| 2 N | 368.7 (3) | .53 | 6.7 (2) | .11 |
| D1-D2 | 371.1 (3) | .53 | NM | NA |
| D4-CK | 345.6 (8) | .90 | 21.6 (6) | .03 |
| D′-D3 | 179.5 (16) | .01 | 2.1 (14) | <.001 |
| A1-A3 | 218.3 (14) | .05 | 9.6 (11) | .84 |
| Intronic | 165.3 (5) | .13 | NA | NA |
| Double mutations | 214.0 (9) | .04 | 4.2 (5) | .72 |
| FVIII:C | ||||
| No mutation | 486.8 (19) | — | 6.2 (9) | — |
| 2 N | 407.1 (3) | .53 | 3.4 (3) | .04 |
| D1-D2 | 442.6 (3) | .53 | NM | NA |
| D4-CK | 686.0 (8) | .07 | 5.4 (6) | .39 |
| D′-D3 | 317.4 (16) | .01 | 2.0 (15) | <.001 |
| A1-A3 | 298.0 (14) | .001 | 6.2 (11) | .65 |
| Intronic | 367.0 (5) | .61 | NA | NA |
| Double mutations | 379.0 (9) | .22 | 3.3 (5) | .09 |
— indicates reference group; NM, half-life not measurable since peak occurred at 240 minutes; and NA, not available.
P value for the considered variable against the no-mutations subgroup.